Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV

Abbvie Inc

May 14 • 03:07PM ET

161.18

Dollar change -0.10
Percentage change -0.06	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO IVV VTV SCHD VIG VYM VHT IWF DGRO

Scroll to Statements

Index	S&P 500	P/E	47.99	EPS (ttm)	3.36	Insider Own	0.11%	Shs Outstand	1.77B	Perf Week	-0.84%
Market Cap	284.62B	Forward P/E	13.37	EPS next Y	12.05	Insider Trans	-19.21%	Shs Float	1.76B	Perf Month	-0.30%
Income	5.95B	PEG	7.88	EPS next Q	3.06	Inst Own	72.15%	Short Float	0.82%	Perf Quarter	-6.99%
Sales	54.40B	P/S	5.23	EPS this Y	1.13%	Inst Trans	0.10%	Short Ratio	2.56	Perf Half Y	16.30%
Book/sh	4.53	P/B	35.54	EPS next Y	7.29%	ROA	4.20%	Short Interest	14.48M	Perf Year	9.53%
Cash/sh	10.23	P/C	15.75	EPS next 5Y	6.09%	ROE	55.92%	52W Range	130.96 - 182.89	Perf YTD	4.01%
Dividend Est.	6.25 (3.88%)	P/FCF	13.02	EPS past 5Y	-5.77%	ROI	8.29%	52W High	-11.87%	Beta	0.59
Dividend TTM	6.06 (3.76%)	Quick Ratio	0.83	Sales past 5Y	11.76%	Gross Margin	68.99%	52W Low	23.08%	ATR (14)	3.02
Dividend Ex-Date	Apr 12, 2024	Current Ratio	0.94	EPS Y/Y TTM	-21.01%	Oper. Margin	31.87%	RSI (14)	39.83	Volatility	1.16% 1.86%
Employees	50000	Debt/Eq	9.24	Sales Y/Y TTM	-4.12%	Profit Margin	10.94%	Recom	1.97	Target Price	182.92
Option/Short	Yes / Yes	LT Debt/Eq	7.97	EPS Q/Q	496.96%	Payout	220.33%	Rel Volume	0.42	Prev Close	161.28
Sales Surprise	3.19%	EPS Surprise	2.24%	Sales Q/Q	0.70%	Earnings	Apr 26 BMO	Avg Volume	5.66M	Price	161.18
SMA20	-1.38%	SMA50	-5.77%	SMA200	2.01%	Trades		Volume	2,090,801	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-10-23	Upgrade	SVB Securities	Underperform → Market Perform	$135 → $153
Nov-18-22	Initiated	Credit Suisse	Outperform	$170
Nov-08-22	Downgrade	Societe Generale	Buy → Hold
Aug-01-22	Downgrade	Atlantic Equities	Overweight → Neutral	$178 → $162
May-23-22	Initiated	SVB Leerink	Underperform	$140
May-06-22	Downgrade	Daiwa Securities	Outperform → Neutral	$150
Apr-06-22	Resumed	Morgan Stanley	Overweight	$192
Feb-28-22	Downgrade	UBS	Buy → Neutral	$129 → $147

Show Previous Ratings

Today 12:10PM	AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal (Zacks)
09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
08:00AM	Unlocking Intrinsic Value: Analysis of AbbVie Inc (GuruFocus.com)
06:30AM	3 Magnificent Stocks That Are Passive Income Machines (Motley Fool)
May-13-24 04:51PM	AbbVie joins psychedelic push, inks $2B+ next-gen neuro deal with Gilgamesh (FierceBiotech.com)
11:44AM	Loading…
11:44AM	12 Undervalued Stocks That Just Raised Their Dividends (Insider Monkey)
11:09AM	What Is the Dividend Payout for AbbVie Stock? (Motley Fool)
09:34AM	AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders (MT Newswires)
08:39AM	AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders (PR Newswire)
May-11-24 08:38AM	Earn $1000 Every Month From These 3 Stocks (Motley Fool)
03:50AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. (Motley Fool)
May-10-24 12:59PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:30AM	3 Rock-Solid Dividend Stocks That Are Ideal for Retirees (Motley Fool)
May-09-24 03:53PM	REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:11AM	Q1 2024 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
02:10PM	Loading…
May-08-24 02:10PM	Teva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings (Barrons.com)
10:49AM	AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine (MT Newswires)
09:37AM	Teva Stock Is Powering Ahead as Schizophrenia News Offsets Mixed Earnings (Barrons.com)
08:32AM	Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190 (MT Newswires)
08:00AM	QULIPTA (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults (PR Newswire)
May-07-24 04:30PM	Teva Earnings Are Soon. What Could Keep the Stock Gains Going. (Barrons.com)
02:50PM	15 Best S&P 500 Dividend Stocks To Buy Now (Insider Monkey)
02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
10:24AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript (Insider Monkey)
May-06-24 02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
08:38AM	10 Best May Dividend Stocks To Buy (Insider Monkey)
08:00AM	AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
May-05-24 01:44PM	3 Reasons to Buy AbbVie Stock on the Dip (Motley Fool)
May-04-24 01:01AM	Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight (GuruFocus.com)
May-03-24 12:38PM	Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:11PM	Loading…
May-02-24 12:11PM	Top 25 Stocks in the S&P 500 by Index Weight Right Now (Insider Monkey)
03:01AM	The top pharmaceutical companies by R&D expenditure (Pharmaceutical Technology)
May-01-24 01:46PM	CVS stresses 'margins over membership' to offset Medicare pressure (Yahoo Finance)
01:46PM	CVS stock plunges after earnings numbers one analyst 'did not even believe' (Yahoo Finance)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Apr-30-24 01:50PM	7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns (InvestorPlace)
12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
11:45AM	AbbVie (ABBV) Could Be a Great Choice (Zacks)
08:38AM	AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	AbbVie Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
06:32AM	Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing (InvestorPlace)
Apr-29-24 04:06PM	AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales (Investor's Business Daily)
11:24AM	BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating (MT Newswires)
08:37AM	Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 (MT Newswires)
08:24AM	Barclays Adjusts Price Target on AbbVie to $187 From $195 (MT Newswires)
Apr-28-24 06:54PM	Dividend Stock Portfolio For Income: Top 15 Stocks (Insider Monkey)
06:49PM	What is an Annuity for Retirement? 15 Dividend Stocks to Buy Instead (Insider Monkey)
07:17AM	12 Under-the-Radar High Dividend Stocks to Invest in Now (Insider Monkey)
04:20AM	Better Dividend Stock: AbbVie or Johnson & Johnson? (Motley Fool)
Apr-27-24 07:15AM	3 Dividend Stocks to Buy and Hold for the Next Decade (Motley Fool)
03:07AM	AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ... (GuruFocus.com)
01:24AM	Q1 2024 AbbVie Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-26-24 05:31PM	Abbvie stock falls amid growing biosimilar competition (Yahoo Finance Video)
04:08PM	AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That (Investor's Business Daily)
04:07PM	Why AbbVie Stock Stumbled Today Despite the Earnings Beat (Motley Fool)
03:15PM	AbbVie (ABBV) Q1 2024 Earnings Call Transcript (Motley Fool)
03:04PM	AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump (Investopedia)
01:30PM	Microsoft, Alphabet earnings fuel stock rally: Yahoo Finance (Yahoo Finance Video)
01:04PM	Analyst Report: AbbVie Inc. (Morningstar Research)
12:10PM	AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View (Zacks)
11:52AM	ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:02AM	Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks (Pharmaceutical Technology)
11:02AM	AbbVie's newer drugs are offsetting losses of the world's once best-selling medication (Quartz)
10:30AM	AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:58AM	AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop (Barrons.com)
09:16AM	Sector Update: Health Care Stocks Mixed Premarket Friday (MT Newswires)
09:11AM	AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges (GuruFocus.com)
09:03AM	AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title (Investor's Business Daily)
08:45AM	AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:07AM	AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update (RTT News)
08:06AM	AbbVie's Q1 Adjusted Earnings Fall, Net Revenue Rises; 2024 Adjusted Profit Outlook Lifted (MT Newswires)
07:44AM	AbbVie lifts profit forecast after Skyrizi sales beat expectations (Reuters)
07:43AM	AbbVie: Q1 Earnings Snapshot (Associated Press Finance)
07:36AM	AbbVie raises annual profit forecast on strong Skyrizi sales (Reuters)
07:35AM	AbbVie Reports First-Quarter 2024 Financial Results (PR Newswire)
07:00AM	PCE reading, Microsoft, Alphabet jump on earnings: Yahoo Finance (Yahoo Finance Video)
Apr-25-24 04:48PM	Cigna to offer Humira rivals with $0 copay at specialty pharmacy (Reuters)
10:58AM	AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint (MT Newswires)
08:44AM	UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study (Reuters)
08:15AM	REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study (Reuters)
08:00AM	New Data Show RINVOQ (upadacitinib) Demonstrated Superiority Versus DUPIXENT (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study (PR Newswire)
Apr-23-24 03:09PM	Nvidia will soar 21% to $1,000 as its new AI chip slams would-be rivals, Morgan Stanley says. Its among 10 stocks set to surge (Fortune)
12:38PM	UPDATE 1-US CDC warns of harmful reactions to fake Botox injections (Reuters)
12:14PM	US CDC warns of harmful reactions to fake Botox injections (Reuters)
09:15AM	Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
08:00AM	Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands (PR Newswire)
Apr-22-24 12:56PM	AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? (Zacks)
09:47AM	Buying the Dip in These 3 Undervalued Dividend Stocks (Motley Fool)
Apr-21-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-19-24 04:11PM	The Bad News Heading Into AbbVie's First-Quarter Earnings Report (Investor's Business Daily)
10:00AM	Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline (Zacks)
Apr-18-24 03:44PM	Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study (Benzinga)
12:18PM	Heard on the Street: AbbVies Bet on a Neuroscience Drug Maker Just Got Better (The Wall Street Journal)
08:31AM	Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients With Giant Cell Arteritis (PR Newswire)
06:30AM	Cerevel, in major surprise, finds success in late-stage Parkinsons study (BioPharma Dive)
Apr-17-24 05:45PM	AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Apr-16-24 10:21AM	UPDATE 1-US FDA warns of harmful reactions to fake Botox injections (Reuters)
10:01AM	US FDA says counterfeit versions of Botox found in multiple states (Reuters)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:00AM	Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc (GuruFocus.com)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Mar 20 '24	Sale	176.30	21,082	3,716,757	55,903	Mar 22 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Option Exercise	61.36	26,110	1,602,110	119,890	Mar 20 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Sale	178.79	58,949	10,539,508	60,941	Mar 20 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Option Exercise	61.36	45,700	2,804,152	89,517	Mar 05 05:30 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Sale	177.27	75,680	13,415,503	13,837	Mar 05 05:30 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Option Exercise	58.30	21,560	1,257,012	167,524	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Sale	176.45	68,879	12,153,957	98,645	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 29 '24	Sale	177.39	9,891	1,754,555	10,397	Mar 01 05:50 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 29 '24	Sale	176.65	5,144	908,688	6,983	Mar 01 05:50 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Feb 28 '24	Sale	177.27	138,616	24,572,458	519,099	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Option Exercise	137.36	13,753	1,889,115	41,926	Feb 27 05:10 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Option Exercise	61.36	14,140	867,630	41,205	Mar 01 05:50 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Sale	177.44	14,140	2,509,002	27,065	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Sale	177.51	13,753	2,441,295	28,173	Feb 27 05:10 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Option Exercise	58.88	52,870	3,112,986	296,814	Feb 23 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Sale	173.71	52,870	9,184,048	243,944	Feb 23 05:00 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Dec 26 '23	Sale	154.72	2,912	450,545	55,903	Dec 28 05:00 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Aug 01 '23	Sale	148.58	60,000	8,914,800	565,294	Aug 02 05:07 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Jul 31 '23	Sale	149.15	18,500	2,759,275	625,294	Aug 02 05:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience